PharmaMar announced positive preclinical results for an ADC candidate, showing that the traditional chemistry-based pharma companies are shifting towards the new generation of biologicals.
PharmaMar is an oncology pharma in Madrid mining a vast source for drug discovery: marine organisms. The company is now pivoting to a more innovative technology with the announcement of positive in vitro results of an antibody-drug conjugate (ADC) candidate, MI130110, against fibrosarcoma and multiple myeloma. Which means the popular ADC field has managed to attract yet another company into what could be a major breakthrough in cancer therapy.
Immuno-oncology stole the show during the last decade by promising a cure for cancer. However, the deaths of five patients in Juno’s CAR-T trial are a clear indicative of the challenges this field is facing. While scientists work on it, ADCs offer an effective alternative capable of overcoming tumor resistance, preventing metastasis and relapse, and most importantly: less expensive than CAR-T.
It’s then clear why companies like PharmaMar, as well as big pharma such as Roche,